Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company’s supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.
FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL
Tuesday, January 28, 2014
FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment